Positive study enables valuable repositioning of new antifibrotic drug candidates by a growing number of pharma companies
, /PRNewswire/ — MeCo Diagnostics, a venture-backed startup dedicated to unlocking a new therapeutic modality for cancer, has announced a publication in Clinical Cancer Research, the leading clinical journal of the American Association for Cancer Research (AACR). The article details a successful Phase 2 study of 130 patients with breast cancer, conducted in collaboration with the Spanish National Cancer Research Centre (CNIO), following a pre-specified analysis plan to evaluate long-term survival after antifibrotic therapy. This study establishes the MeCo Score as the first clinically validated predictive biomarker for antifibrotic therapy—a fundamentally new way to fight breast cancer.
Patients with early-stage, HER2-negative breast tumors with High MeCo Scores who received nintedanib (antifibrotic therapy) plus chemotherapy experienced a 62% reduction in risk of recurrence compared to chemotherapy alone, with a median follow-up time of 9.7 years (P<0.05). This combined …